Beta-lactam compounds modulating T cell activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective compositions and methods to directly and significantly enhance T cell activity, particularly for anti-tumor and anti-viral immune responses, and there is a need for treatments that can augment tumor rejection without inducing antibacterial resistance or adverse effects on commensal bacteria.
Innovation Solution
The use of specific beta-lactam compounds such as cefuroxime, penicillin, ceftriaxone, clavulanic acid, 6-aminopenicillanic acid, and tazobactam, either alone or conjugated to albumin, to modulate T cell activity and enhance immune responses, promoting tumor rejection and immune-mediated tumor rejection without the need for antibacterial doses or regimes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If beta-lactam antibiotics are used to treat bacterial infections, then bacterial cell wall synthesis is inhibited and bacterial cells are killed, but bacterial resistance develops through beta-lactamase enzyme production
Solution Approach 1:
The patent introduces beta-lactamase inhibitors (clavulanic acid, tazobactam, 6-APA) as intermediary substances that bind to and inhibit bacterial beta-lactamase enzymes, preventing the degradation of beta-lactam antibiotics and restoring their antibacterial efficacy against resistant strains
Solution Approach 2:
The patent combines beta-lactam antibiotics with beta-lactamase inhibitors to create composite therapeutic formulations (e.g., amoxicillin-clavulanic acid, piperacillin-tazobactam) that simultaneously provide antibacterial activity and resistance prevention through synergistic mechanisms
2Reliability
If conventional beta-lactam antibiotics are used to enhance T cell activity, then T cell-mediated immune responses are augmented, but antibacterial effects and resistance are induced
Solution Approach 1:
The patent modifies the dosage parameters by using sub-antibacterial doses of beta-lactam compounds that are sufficient to modulate T cell activity and enhance immune responses but too low to produce significant antibacterial effects or select for resistant bacterial populations
Solution Approach 2:
The patent exploits the selective binding of beta-lactams to specific proteins (such as albumin and T cell surface proteins) to achieve localized immunomodulatory effects at the tissue level without system-wide antibacterial activity
3Reliability
If beta-lactam compounds are administered at antibacterial doses, then bacterial infections are treated effectively, but adverse effects on commensal bacteria and resistance are promoted
Solution Approach 1:
The patent applies partial action by using sub-antibacterial doses that provide sufficient immunomodulatory benefit without achieving full antibacterial efficacy, thereby avoiding excessive disruption to commensal bacterial populations while still obtaining therapeutic advantage
Data Source
AI summary
Compositions and methods are provided, comprising at least one beta-lactam compound selected from the group consisting of cefuroxime, a penicillin, ceftriaxone, clavulanic acid, 6-aminopenicillanic acid (6-APA) and tazobactam, for enhancing T cell mediated immune responses in a subject, such as anti-tumor and anti-viral immune responses.